Bristol Myers Company Profile

What is the competitive landscape for BRISTOL MYERS

BRISTOL MYERS has seventy-six approved drugs.

There are twelve US patents protecting BRISTOL MYERS drugs.

There are six hundred and four patent family members on BRISTOL MYERS drugs in fifty-one countries and one hundred and forty-six supplementary protection certificates in eighteen countries.

Summary for Bristol Myers

International Patents:	604
US Patents:	12
Tradenames:	65
Ingredients:	58
NDAs:	76
Drug Master File Entries:	1

Drugs and US Patents for Bristol Myers

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Bristol Myers Squibb	COUMADIN	warfarin sodium	TABLET;ORAL	009218-025	Nov 18, 1996		DISCN	Yes	No
Bristol Myers Squibb	STILBESTROL	diethylstilbestrol	INJECTABLE;INJECTION	004056-005	Approved Prior to Jan 1, 1982		DISCN	No	No
Bristol Myers Squibb	STILBETIN	diethylstilbestrol	TABLET, DELAYED RELEASE;ORAL	004056-013	Approved Prior to Jan 1, 1982		DISCN	No	No
Bristol Myers Squibb	REVLIMID	lenalidomide	CAPSULE;ORAL	021880-002	Dec 27, 2005	AB	RX	Yes	No
Bristol Myers Squibb	VESPRIN	triflupromazine hydrochloride	TABLET;ORAL	011123-003	Approved Prior to Jan 1, 1982		DISCN	No	No

Expired US Patents for Bristol Myers

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Bristol Myers Squibb	PRAVIGARD PAC (COPACKAGED)	aspirin; pravastatin sodium	TABLET;ORAL	021387-006	Jun 24, 2003	5,030,447*PED
Bristol Myers Squibb	REVLIMID	lenalidomide	CAPSULE;ORAL	021880-002	Dec 27, 2005	8,648,095
Bristol Myers Squibb	PRAVIGARD PAC (COPACKAGED)	aspirin; pravastatin sodium	TABLET;ORAL	021387-005	Jun 24, 2003	4,346,227*PED
Bristol Myers Squibb	PRAVACHOL	pravastatin sodium	TABLET;ORAL	019898-003	Oct 31, 1991	5,622,985*PED
Bristol Myers Squibb	VIDEX	didanosine	FOR SOLUTION;ORAL	020155-005	Oct 9, 1991	5,616,566*PED

Paragraph IV (Patent) Challenges for BRISTOL MYERS drugs

Drugname	Dosage	Strength	Tradename	Submissiondate
	Tablets	0.5 mg and 1 mg		2010-06-14
	Tablets	30 mg		2005-06-01
	Tablets	80 mg and 140 mg		2011-06-16
	Capsules	25 mg		2010-07-12
	Capsules	2.5 mg and 20 mg		2016-07-12
	Capsules	100 mg and 150 mg		2010-03-19
	Tablets	600 mg		2009-04-09
	Nasal Spray	4 mg/spray		2016-07-15
	Tablets	2.5 mg and 5 mg		2016-12-28
	Tablets	20 mg, 50 mg, 70 mg and 100 mg		2010-06-28
	Tablets	80 mg and 140 mg		2011-06-17
	Delayed-release Capsules	200 mg, 250 mg and 400 mg		2004-06-01
	Capsules	5 mg, 10 mg and 15 mg		2010-08-30
	Capsules	300 mg		2009-07-20
	Capsules	200 mg		2010-02-16
	Capsules	50 mg, 100 mg and 200 mg		2016-11-03

International Patents for Bristol Myers Drugs

Country	Patent Number	Estimated Expiration
Croatia	P20100166
Austria	E453630
Slovenia	3246021
Hong Kong	1104968
Japan	6067226

Supplementary Protection Certificates for Bristol Myers Drugs

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2487163	PA2016039,C2487163	Lithuania		PRODUCT NAME: KOBICISTATAS ARBA FARMACINIU POZIURIU PRIIMTINA JO DRUSKA IR ATAZANAVIRAS ARBA FARMACINIU POZIURIU PRIIMTINA JO DRUSKA, YPAC ATAZANAVIRO SULFATAS; REGISTRATION NO/DATE: EU/1/15/1025 20150713
1353647	2011/024	Ireland		PRODUCT NAME: AZTREONAM LYSINE; REGISTRATION NO/DATE: EU/1/09/543/001 20090923
1427415	31/2011	Austria		PRODUCT NAME: APIXABAN UND PHARMAZEUTISCH VERTRAEGLICHE SALZE DAVON; REGISTRATION NO/DATE: EU/1/691/001-005 (MITTEILUNG) 20110520
1453521	122015000093	Germany		PRODUCT NAME: LEVONORGESTREL UND ETHINYLESTRADIOL; NAT. REGISTRATION NO/DATE: 87675.00.00 20150720; FIRST REGISTRATION: SLOWAKEI 17/0017/15-S 20150129
1169038	2013/003	Ireland		PRODUCT NAME: DASATINIB AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF.; REGISTRATION NO/DATE: EU/1/06/363/001-015 20061120

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

• Bristol
• Bristol Myers
• Bristol Myers Squibb
• Bristol-myers
• Bristol-myers Squibb

Pharmaceutical Competitive Landscape Analysis: BRISTOL MYERS – Market Position, Strengths & Strategic Insights

Last updated: October 15, 2025

---

Introduction

Bristol Myers Squibb (BMS) stands as a formidable player in the global pharmaceutical industry, recognized for its robust portfolio in oncology, immunology, cardiovascular, and hematology therapeutics. As the industry evolves amid innovation, regulatory changes, and shifting market dynamics, understanding BMS’s strategic position offers valuable insights for stakeholders. This analysis explores BMS’s market standing, core strengths, competitive differentiators, and strategic outlook within the complex global pharmaceutical landscape.

---

Market Position of Bristol Myers Squibb

Global Market Footprint

Bristol Myers Squibb ranks among the top-tier pharmaceutical companies worldwide, with a substantial revenue base driven by its diversified product portfolio. In 2022, the company reported annual revenues exceeding $46 billion, bolstered by key blockbuster drugs such as Revlimid (lenalidomide), Eliquis (apixaban), and Opdivo (nivolumab) (BMS Annual Report, 2022). The company's strategic acquisitions, notably Celgene in 2019, significantly expanded its footprint in oncology and hematology segments, consolidating its position among industry leaders.

Strategic Focus Areas

• Oncology & Hematology: With a dominant portfolio, BMS commands a significant share in hematologic cancers and solid tumors.
• Immunology: Products like Orencia (abatacept) reinforce its presence in autoimmune diseases.
• Cardiovascular & Hematology: Collaborative growth driven by Eliquis, renowned for anticoagulation indications.

Geographical Reach

BMS maintains a broad international presence, with a robust pipeline in North America, Europe, and increasingly in emerging markets. Its global strategic collaborations facilitate market penetration, particularly in Asia-Pacific and Latin America, key growth areas amidst rising healthcare demands.

---

Core Strengths of Bristol Myers Squibb

1. Robust Product Pipeline

BMS invests heavily in R&D, with a pipeline comprising over 50 compounds in various stages of development [1]. Its strategic acquisitions, particularly Celgene’s pipeline, have yielded an extensive array of candidates focused on oncology, immunology, and fibrosis, positioning it for sustained growth.

2. Leadership in Oncology and Immunology

The company's flagship drugs, such as Revlimid and Opdivo, enjoy market exclusivity and high revenue generation. Opdivo, a PD-1 checkpoint inhibitor, has become a cornerstone in cancer immunotherapy, complemented by recent approvals of combination therapies, enhancing its competitive advantage [2].

3. Strategic Acquisitions and Collaborations

The Celgene acquisition exemplifies BMS's strategic growth approach, enabling access to promising assets in oncology and anti-inflammatory agents. Collaborations with tech firms for drug discovery and biomarker development further strengthen its innovation capacity.

4. Financial Strength and R&D Investment

BMS’s financial stability allows sustained R&D spending (~$4.5 billion annually), facilitating innovation and pipeline expansion. Its strong cash flow supports strategic mergers, acquisitions, and global market expansion initiatives.

5. Strong Market Branding and Customer Loyalty

Established reputation for high-quality, innovative products sustains its competitive edge. Its focus on patient-centric solutions and regulatory compliance enhances brand equity among healthcare providers and patients.

---

Strategic Insights

Market Challenges and Opportunities

• Patent Expirations: Drugs like Revlimid face generic competition, pressuring revenue streams. Strategic pipeline diversification mitigates reliance on flagship products.

• Regulatory & Pricing Pressures: Increased scrutiny over drug prices necessitates value-based approaches and efficiency in R&D and commercialization strategies.

• Emerging Markets: Growing healthcare infrastructure offers significant opportunities, but requires tailored market entry strategies, including partnerships and local manufacturing.

Innovation and Personalized Medicine

BMS actively invests in precision medicine, leveraging biomarkers and genetic data to tailor therapies. This approach enhances efficacy, reduces adverse effects, and offers differentiation in competitive landscapes.

Digital Transformation

Integrating digital health technologies, real-world evidence, and data analytics supports drug development and post-market surveillance. BMS’s collaborations with pharma tech firms exemplify its forward-looking stance.

Strategic Mergers & Alliances

Continuing consolidation through acquisitions and alliances will further diversify BMS’s portfolio and expand market access. Potential future targets may include promising biotech firms specializing in cell and gene therapies.

Sustainability & Corporate Responsibility

Emphasizing sustainable practices and equitable access aligns with global healthcare trends, positively impacting corporate reputation and stakeholder trust.

---

Competitive Positioning and Differentiation

• Innovation Leadership: BMS’s substantial R&D budget, combined with a targeted pipeline, positions it as an innovation pioneer, especially in immuno-oncology.
• Market Exclusivity and Intellectual Property: Strategic patent filings and lifecycle management extend product competitiveness.
• Diverse Portfolio: Cross-segment diversification mitigates risks associated with dependence on a single therapeutic area.
• Global Reach: Extensive market penetration supports revenue stability amid regional regulatory and economic fluctuations.

---

Key Strategic Recommendations

• Accelerate Digital and Data-enabled Innovation: Invest further in AI-driven drug discovery and real-world evidence platforms.
• Diversify Portfolio Ahead of Patent Cliff: Focus on expanding into cell and gene therapies, biosimilars, and novel modalities.
• Strengthen Presence in Emerging Markets: Tailor strategies to local needs, enhance manufacturing capabilities, and build strategic alliances.
• Enhance Patient-centric Solutions: Grow patient support programs and value-based healthcare offerings.
• Navigate Regulatory Landscapes Proactively: Engage early with regulators on novel therapies to streamline approval processes.

---

Key Takeaways

• Bristol Myers Squibb maintains a leading market position driven by its diversified, innovative portfolio in oncology, immunology, and hematology.
• Strategic acquisitions like Celgene significantly bolster its pipeline and market reach, underscoring a growth-oriented approach.
• Its financial robustness underpins substantial R&D investment, vital for sustaining innovation leadership.
• Challenges such as patent expirations and pricing pressures require continuous pipeline diversification and value demonstration.
• Expanding in emerging markets and embracing digital transformation present opportunities for scalable growth.
• Long-term success hinges on agility in navigating regulatory changes, integrating personalized medicine, and cultivating collaborative ecosystems.

---

FAQs

1. How has the Celgene acquisition impacted Bristol Myers Squibb’s market position?
The acquisition expanded BMS’s oncology and hematology portfolio, particularly with Revlimid, reinforcing its leadership. It also enhanced pipeline breadth and R&D capabilities, positioning BMS for sustained innovation and market dominance in oncology.

2. What are the main growth drivers for BMS over the next five years?
Key drivers include the commercialization of pipeline candidates, growth in immuno-oncology therapies like Opdivo, expanding presence in emerging markets, and strategic innovation in cell and gene therapies.

3. How is BMS addressing patent expirations of flagship drugs?
BMS is diversifying its portfolio, investing in new therapeutic areas, and developing novel formulations and combination therapies. It’s also focusing on accelerating pipeline approvals and expanding into high-growth areas like cell therapy.

4. What role does digital health play in BMS’s strategy?
Digital health enables more precise patient targeting, real-world evidence collection, and efficient clinical trial designs. BMS’s collaborations with tech firms aim to improve drug efficacy, safety, and patient engagement.

5. How does BMS navigate regulatory and pricing pressures globally?
BMS adopts proactive engagement with regulators, emphasizes value-based pricing strategies, enhances transparency, and invests in demonstrating the health economic benefits of its therapies.

---

Sources

[1] Bristol Myers Squibb Annual Report 2022.
[2] FDA Product Approvals and News Archives.